OXiGENE gives update on Zybrestat

17 December 2007

OXiGENE, a clinical-stage, US biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, says that its chief executive, Richard Chin, has presented a corporate update to investors in Stockholm, Sweden.

Included in the presentation was an update on the progress of the firm's ongoing Phase II/III pivotal registration study of Zybrestat (combretastatin A4 phosphate) for anaplastic thyroid cancer. OXiGENE indicated that it has initiated a total of four clinical trial sites in the USA and India, and anticipates starting two to three additional sites prior to year-end. Additional regulatory submissions and reviews are in progress to support initiation of further study sites in the USA, Europe, Russia and Israel beginning in January 2008. Based on meetings with investigators from around 30 sites conducted this fall in India, the USA and Europe, OXiGENE anticipates having substantially all of the study's clinical trial sites initiated by mid-2008. As a result, it expects to reach the planned interim analysis by mid-2009.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight